Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.48 |
| ▸ | HTR6 | P50406 | 5/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.42 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | UBE2N | P61088 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25422412 | 1.00 | DYRK1B (0.48) | DYRK1BHTR6FLT3L3MBTL1DYRK1A | |
| SCHEMBL28859616 | 0.87 | L3MBTL1 (0.60) | HTR6FLT3L3MBTL1DYRK1ADRD2 | |
| SCHEMBL25420973 | 0.81 | DYRK1A (0.55) | DYRK1BHTR6L3MBTL1DYRK1ANFATC1 | |
| SCHEMBL30461646 | 0.79 | HTR6 (0.61) | HTR6L3MBTL1DYRK1ANFATC1GSK3B | |
| SCHEMBL25422336 | 0.79 | HTR6 (0.61) | HTR6L3MBTL1DYRK1ANFATC1GSK3B | |
| SCHEMBL28216508 | 0.76 | L3MBTL1 (0.60) | HTR6FLT3L3MBTL1DRD2HTR2A | |
| SCHEMBL13051115 | 0.76 | HTR6 (0.51) | DYRK1BHTR6FLT3DYRK1ACDK2 | |
| SCHEMBL25420439 | 0.74 | HTR6 (0.51) | HTR6L3MBTL1CA2CA9CYP19A1 | |
| SCHEMBL12450003 | 0.74 | HTR6 (0.51) | HTR6L3MBTL1PDPK1CA2CA9 | |
| SCHEMBL30461713 | 0.74 | HTR6 (0.51) | HTR6L3MBTL1CA2CA9CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099442-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES INC | 2025-03-27 | — | — | US | disclosed |
| EP-4444721-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | Prothena Biosciences Limited (IE) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023107722-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2023-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099442-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | DYRK2, DYRK1A, DYRK1B | DYRK1B 3/4885HTR6 521/4885FLT3 883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.